Medicare Will Target Rx Fraud in 2006
Fearing an upsurge in pharmacyreimbursement fraud when the MedicarePart D prescription drug programtakes effect next year, Medicare officialshave announced the creation ofseveral new operating units. The aim ofthese units will be "to identify problemareas through trend analysis of claimsdata, and to oversee potential fraudareas in the Discount Drug Card andPrescription Drug programs."
Testifying at hearings of the SenateHomeland Security Subcommittee,Centers for Medicare and Medicaid Services(CMS) Financial ManagementDirector Tim Hill told Congress thatthe newly created divisions are among"several specific actions [that] havebeen taken by CMS to ensure that federaldollars are being properly spentand fraudulent billings are stoppedwhen they are detected."
Part of the crackdown will involvethe establishment of a new CMS satelliteoffice in Los Angeles to help "curtailfraudulent spending in high-riskareas," Hill said.
In addition, the CMS official servednotice that pharmacies that have beeninvolved in Medicaid billing abusesmay be flagged for special scrutinyunder the new Medicare drug program."For the first time, Medicare claimsand Medicaid claims are being jointlydata-mined to identify fraud andabuse," Hill explained. "In many cases,a small number of crooked providersare exploiting both programs."
Mr. Rankin is a freelance medical writer.
Articles in this issue
about 20 years ago
Article
Neuropathic Pain: Diagnosis, Treatment, and the Pharmacist's Role in Patient Careabout 20 years ago
Article
Comorbidity of GI Motility Disorders: Clinical Implications for Patients and PharmacistsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025